首页> 外文OA文献 >Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials

【2h】

Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials

机译：与抗PD-1 / PD-L1和抗CTLA-4抑制剂的存活和免疫相关不良事件的结合，单独或它们对治疗癌症的组合：13项临床试验的系统审查和荟萃分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Leyin Zhang; Leitao Sun; Yiwen Zhou; Jieru Yu; Yingying Lin; Harpreet S. Wasan; Minhe Shen; Shanming Ruan;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials [J] . B. El Osta, F. Hu, R. Sadek, Critical reviews in oncology/hematology . 2017,第期

机译：并非所有免疫检查点抑制剂都是相等的：癌症试验中免疫相关不良事件的荟萃分析和系统审查
2. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis [J] . Leitao Sun, Leyin Zhang, Jieru Yu, Scientific reports. . 2020,第1期

机译：抗PD-1 / PD-L1抑制剂治疗晚期或转移性癌症的临床疗效和安全性：系统评价和荟萃分析
3. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients [J] . Cortellini Alessio, Buti Sebastiano, Agostinelli Veronica, Seminars in Oncology . 2019,第4a5期

机译：对晚期癌症患者检查点抑制剂的免疫相关不良事件发生与临床结果之间的新出现关联的系统综述
4. ADVERSE EVENT REPORTING IN COMPANION ANIMAL CLINICAL TRIALS EVALUATING CANCER THERAPY: A SYSTEMATIC REVIEW [C] . Michelle Giuffrida Conference of the American^College^of^Veterinary^Internal^Medicine . 2016

机译：伴侣动物临床试验评估癌症治疗的不良事件报告：系统审查
5. Immune-Related Adverse Events in Cancer Patients Being Treated with Immune Checkpoint Inhibitors [D] . Byrne, Margaret M. 2021

机译：用免疫检查点抑制剂治疗癌症患者免疫相关不良事件
6. Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials [O] . Leyin Zhang, Leitao Sun, Yiwen Zhou, 2021

机译：与抗PD-1 / PD-L1和抗CTLA-4抑制剂的存活和免疫相关不良事件的结合单独或它们对治疗癌症的组合：13项临床试验的系统审查和荟萃分析
7. Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis [O] . Zhirui Zhou, Shengxiang Ren, Lingxiao Chen, 2021

机译：在先进的NSCLC中，无PD-1 / PD-L1抑制剂的无进展存活和整体存活之间的治疗效果大小的差异：系统评价和荟萃分析

Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials

著录项

引文网络

相似文献

相关主题

期刊订阅